Vor Biopharma (VOR) Stock Overview
Operates as a clinical-stage cell and genome engineering company. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
VOR Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Vor Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.74 |
| 52 Week High | US$3.29 |
| 52 Week Low | US$0.13 |
| Beta | 2.05 |
| 1 Month Change | -18.69% |
| 3 Month Change | 684.84% |
| 1 Year Change | 65.71% |
| 3 Year Change | -63.06% |
| 5 Year Change | n/a |
| Change since IPO | -95.36% |
Recent News & Updates
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Sep 11
Vor Biopharma: Chinese Win Sets The Direction, But There Is Still Much Uncertainty
Aug 13Recent updates
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Sep 11Vor Biopharma: Chinese Win Sets The Direction, But There Is Still Much Uncertainty
Aug 13Calculating The Intrinsic Value Of Vor Biopharma Inc. (NASDAQ:VOR)
Jun 25We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
Apr 08Vor Biopharma: Short On Cash, Too Much Uncertainty For Now
Feb 24We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
Dec 24Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely
Sep 10We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
May 24Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
Dec 05Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?
Aug 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
May 05Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?
Mar 13We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Oct 19Vor Bio appoints Eyal C. Attar as chief medical officer
Oct 12Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?
Jun 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Mar 05Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Aug 30Vor Biopharma: Targeted Therapies For Transplants
Jun 30We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
May 10Shareholder Returns
| VOR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.2% | -1.8% | 1.7% |
| 1Y | 65.7% | -9.7% | 18.7% |
Return vs Industry: VOR exceeded the US Biotechs industry which returned -9.7% over the past year.
Return vs Market: VOR exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| VOR volatility | |
|---|---|
| VOR Average Weekly Movement | 37.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VOR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VOR's weekly volatility has increased from 26% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 154 | Jean-Paul Kress | www.vorbio.com |
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant.
Vor Biopharma Inc. Fundamentals Summary
| VOR fundamental statistics | |
|---|---|
| Market cap | US$220.43m |
| Earnings (TTM) | -US$1.66b |
| Revenue (TTM) | n/a |
Is VOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VOR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.66b |
| Earnings | -US$1.66b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VOR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/14 16:02 |
| End of Day Share Price | 2025/09/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vor Biopharma Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Carter Gould | Barclays |
| Justin Walsh | B. Riley Securities, Inc. |